Lambert-Eaton myasthenic syndrome (LEMS)

Get to know this rare neuromuscular disorder with a devastating impact



LEMS is a rare, immunemediated disorder of the neuromuscular junction¹⁻³



LEMS affects an estimated 3,000 individuals in the US, most of whom are adults^{4,5}



Debilitating muscle weakness and fatigue characterize LEMS⁶

PREVALENCE

LEMS is the second-most common disorder of neuromuscular transmission.^{2,3}



Affects 1/100,000 individuals in the United States^{4,5}



As many as 50% of individuals suffering from LEMS are currently **undiagnosed or misdiagnosed**⁵


CLINICAL PRESENTATION

LEMS symptoms are insidious and progressive, characteristically beginning with^{5,6}:

- Lower limb weakness and generalized fatigue
- Difficulty rising from a seated position and climbing stairs
- Dry mouth, impotence, or orthostatic hypotension

LEMS is often suspected and diagnosed based on a triad of symptoms^{4,5,7-13}:

- Proximal muscle weakness with a caudal-to-cranial progression
- Autonomic nervous system dysfunction in most patients
- Hyporeflexia or areflexia in some patients



Patients with LEMS report health-related quality of life (HRQoL) scores comparable to debilitating neurological disorders, such as multiple sclerosis.⁶

ETIOLOGY

LEMS is caused by pathogenic autoantibodies that target P/Q-type voltage-gated calcium channels (VGCCs) in the presynaptic membrane of the motor nerve terminal.^{14,15}

Pathogenic Autoantibodies Inhibit Neuromuscular Transmission^{14,15} Impairs entry of calcium ions into the presynaptic nerve terminal of motor neurons Decreased exocytosis of acetylcholine-containing vesicles into the neuromuscular junction neuromuscular junction

SUBSETS OF LEMS

The underlying etiology that drives autoantibody production against VGCCs varies depending on the form of LEMS.



50% to 60% Paraneoplastic LEMS⁵

- Small cell lung cancer (SCLC) is the most predominant malignancy associated with LEMS^{11,16}
 - Screening for a suspected underlying tumor is imperative: ~96% of SCLC cases can be diagnosed within a year of LEMS diagnosis, given regular oncologic surveillance¹⁶
- Tumor LEMS often displays a more rapid, progressive course than non-tumor LEMS⁸




Non-Tumor LEMS⁵

- Preexisting autoimmune conditions have frequently been observed in this patient population¹⁷
- Two-thirds of patients with LEMS display a characteristic HLA genotype (HLA-B8, HLA-DR3, and HLA-DQ2)¹⁷
- Non-tumor LEMS progresses more slowly than tumor LEMS, with fluctuating symptoms⁵

PROGRESSION/BURDEN

LEMS progresses over time and can result in severe debilitation.⁶ In the first 2 years after the onset of LEMS, the prevalence of specific symptoms related to muscle weakness and autonomic dysfunction increases regardless of the type of LEMS.⁸




Even with long-term immunosuppressive therapy, less than half of patients with non-tumor LEMS achieve sustained clinical remission¹⁸



1 in every 4 patients with LEMS requires a wheelchair all the time or for mobilization when away from home¹⁸

MISDIAGNOSIS

Misdiagnosis of LEMS is common, with up to 50% of patients being misdiagnosed or undiagnosed.⁵



LEMS is often confused with a number of other conditions, including⁵:

- Myasthenia gravis
- Generalized myopathies
- Peripheral nerve abnormalities
- Intracranial/spinal cord abnormalities
- Depression

A 2012 cross-sectional study found that the average time lapse between a patient's first consultation with a physician and a confirmed diagnosis of LEMS was 4.4 years.⁶

DIAGNOSTIC METHODS FOR CONFIRMING LEMS

Clearly identifying LEMS symptoms can result in a quicker confirmed diagnosis and effective treatment course.⁵

LEMS may be suspected based on clinical symptomatology and physical signs.⁵ Diagnosis of LEMS may be further confirmed by use of one or both of the following methods:



Anti-Voltage-Gated Calcium Channel Antibody Testing

The presence of anti-VGCC antibodies can be detected in up to 90% of patients with LEMS. As these antibodies are highly specific to LEMS, a positive VGCC antibody test can help rule out other causes of muscular weakness.⁵



Electrodiagnostic Testing

Electrodiagnostic testing demonstrating an increment on high-frequency repetitive nerve stimulation or post-exercise potentiation is a hallmark of LEMS.⁵

Ask your regional account manager about a free diagnostic testing program provided by Catalyst Pharmaceuticals.

References: 1. Muppidi S, Wolfe GI, Barohn RJ. Diseases of the neuromuscular junction. In: Swaiman K, Ashwal S, Ferriero D, Schor N, eds. Pediatric Neurology: Principles and Practice. 5th ed. Philadelphia, PA: Elsevier; 2011:1549-1569. 2. Deenen JC, Horlings CG, Verschuuren JJ, et al. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015;2(1):73-85. 3. Simon JI, Herbison GJ, Levy G. Case report: a case review of Lambert-Eaton myasthenic syndrome and low back pain. Curr Rev Musculoskelet Med. 2011;4(1):1-5. 4. Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann NY Acad Sci. 2003;998:500-508. 5. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107 6. Harms L. Sieb JP, Williams AE, et al. Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Faton myasthenic syndrome: results of a patient interview survey in Germany. J Med Econ. 2012;15(3):521-530. 7. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111(Pt 3):577-596. 8. Wirtz PW, Wintzen AR, Verschuuren JJ. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve, 2005;32(2):226-229. 9. Lorenzoni PJ, Scola RH, Kay CS, Parolin SF, Werneck LC. Non-paraneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases. Arg Neuropsiquiatr. 2010;68(6):849-854. 10. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902-908. 11. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ, Differences in clinical features between the Lambert-Faton myasthenic syndrome with and without cancer; an analysis of 227 published cases. Clin Neurol Neurosurg, 2002;104(4):359-363. 12. Young JD, Leavitt JA. Lambert-Eaton myasthenic syndrome: ocular signs and symptoms. J Neuroophthalmol. 2016;36(1):20-22. 13. Merino-Ramírez MÁ, Bolton CF. Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. Can J Neurol Sci. 2016;43(5):635-647. 14. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467-1474. 15. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997;147(1):35-42. 16. Titulaer MJ, Wirtz PW, Willems LN, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26(26):4276-4281. 17. Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis. 2011;2011:973808. 18. Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry. 2001;70(2):212-217.



© 2020 Catalyst Pharmaceuticals, Inc. All Rights Reserved. Printed in USA. 20LEM0221 July 2020